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Metallodrugs are drugs that contain a metal, and are usually seen with anticancer 
treatments. However, there has been significant development over years that have progressed 
the use of metallodrugs. These drugs can be seen in either an oral form or an injection/infusion. 
Metals have been used throughout the ages in medical applications. We see this in the 16th 
century with syphilis, which was treated with mercury. However, it wasn’t until the 20th century 
when metals really caught the spot light. The first therapeutic metallodrug compound was 
developed in 1909, which was Salvarsan, also used to treat syphilis. Salvarsan, arsenic based, 
was the best option for treating syphilis until penicillin was discovered in 1928 [1,4,14].  
In 1964 Barnett Rosenberg, discovered that  platinum compounds hinder the growth of 
cells. From Rosenberg’s studies the compound cisplatin, a platinum compound, was developed 
in the treatment of cancer cells. This drug was specifically used for ovarian and testicular cancer 
in the late 1970’s. The application of cisplatin provoked an interest in other metal compound 
use in drugs. The problem with metallodrugs is that they have been tricky to develop; a lot of 
metal based drugs have been discovered by chance [1,4,7,14].  
Looking at the 21th century, Medical inorganic chemists wanted to change the 
development of metallodrugs from chance to a rational discovery. When it comes to designing 
metal based drugs the first step is to identify the disease target and the specific molecular 
target associated with the cause of the disease. It is about knowing the disease or disorder of 
choice and then targeting the cause of that disease or disorder. Understanding metals in 
biology is a key base to start from when looking to develop metallodrugs. Knowing a metal’s 
Running head: Impact of Metallodrugs  3 
uptake, trafficking, function and excretion is important. Looking at the characteristics of a metal 
within a cell and/or tissues is a step in development as well as a metals interactions with genes 
and proteins. The majority of drug development comes with the interactions of targeting DNA 
or proteins [1,17,18].  
Understanding how to detect any disease or disorder is crucial. Radiopharmaceuticals is 
a primary way for medical diagnostics and therapy. Radiopharmaceuticals help with diagnosing 
cancer, cardiological disorders, infections, kidney or liver abnormalities and neurological 
disorders [1]. It is possible to find and differentiate between healthy tissue and carcinogenic 
tissue in image analysis before the tissue has ever been taken. The quality of medical scans has 
improved with the help of metallodrugs.   A dominant as well as a majority used isotope, for 
radiopharmaceuticals, is technetium-99m (figure 1). There is a total of 28 FDA approved 
technetium-99m imaging agents. Technetium-99m is a dominant isotope used in 
radiopharmaceuticals because its gamma radiation is easily detected at 140.4KeV, where 
optimal gamma energy range is about 100 to 200keV. Technetium -99m has a wide range of 
oxidation numbers and coordination numbers. Oxidation states ranged from -1 to +7 and 
coordination numbers ranged from 4 to 9. The different properties of technetium -99m has led 
to an open target platform for the development of radiopharmaceuticals. There is a 
disadvantage to technetium -99m and that is that it is in short production. There is an 
alternative to technetium -99m; the isotopes Gallium-67m and gallium-68m. The gallium 
isotopes are used for SPECT and PET scans [1,9] .  
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Mjos, K. D.; Orvig, C. Metallodrugs in Medicinal Inorganic Chemistry. Chemical Reviews  
2014, 114(8), 4540–4563. 
There is a variety of metals that have been used or are in clinical trials as a metallodrug. 
Some metals in particular are gold, vanadium, copper, silver, bismuth and platinum. The uses 
that metals can play in biological conditions is outstanding. They can help a plethora of 
treatments for multiple disorders and diseases. Some of the disorders and diseases they can 
help in treating is arthritis, diabetes, Alzheimer’s, wound healing and vaccines. Three metals in 
     Figure 1: FDA-approved 
metalloradiopharmaceuticals  
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particular, that play a part in helping the treatment of wounds are copper, silver and bismuth. 
Silver helps in the treatment of infections, such as burns as well as treating cysts and abscesses. 
Bismuth assists in treating antimicrobial treatments. One treatment in particular is in treating 
chronic wounds, such as diabetic foot ulcers [1,14,19].   
Metallodrugs can also play a role in the treatment of psychiatric disorders. Lithium 
based drugs in the 1950’s became a very recognizable treatment for bipolar disorders or 
disorders that have strong mood swings. In 1979 there was an oral lithium carbonate drug that 
was approved by the FDA. This drug was useful because it reduced suicide rises and mood 
swings. However, the mechanism for how lithium works is relatively unknown. It is thought to 
protect the nerves system from injury and damage, targeting the amygdala, part of the brain 
that processes negative emotion. It is also thought to regulate neurotransmissions and control 
cellular and intracellular changes in the second messenger system [1]. 
One disorder metallodrugs can add in is rheumatoid arthritis.  Rheumatoid arthritis is an 
inflammatory autoimmune disorder that is painful and incurable. This disorder affects roughly 
one to two percent of people in the world and can cause a total loss of joint movement. There 
are two classifications for drugs to use for this disorder. One is called “first-line” drugs, which 
consist of aspirin and ibuprofen. These drugs are mainly just a way to alleviate pain and 
swelling, nothing more. The second class is “second-line” drugs, which includes methotrexate, 
D-penicillamine and various gold salts. The “second-line” drugs are used for more severe cases 
and can slow the progression of arthritis. Gold salts are considered second line drugs because 
they help on the treatment of slowing the advancement of arthritis. They act as 
immunosuppressants,  and are antirejection drugs, preventing the body from rejection 
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something, it normally would. The FDA has approved several gold (I) arthritis metallodrugs. One 
type of gold salt that is the most common treatment, is gold sodium thiomalate. Gold sodium 
thiomalate did receive negative connotations because of the harmful side effects. As a result, 
methotrexate, an anticancer drug, became a treatment for arthritis. There are positive 
attributes to methotrexate such as having a smaller dosage than gold salts. At 7.5 mg per week, 
an improvement may be seen in three to six weeks. Where gold sodium thiomalate, on the 
other hand, has a dosage between 25 and 50 mg per week and it may take three to six months 
for improvement to be detected. Another advantage of methotrexate is its shorter half-life of 3 
to 10 hours, while gold sodium thiomalate can be left in the body from 3 to 27 days. These are 
positive attributes of methotrexate, but methotrexate has just as many or more harmful side 
effects as gold sodium thiomalate. [1,11]. 
Diabetes is another disease that metallodrugs can help in treating. Throughout the 
world it is estimated that about 347 million people have diabetes. Diabetes can be grouped into 
two types. Type one is insulin dependent and is caused by a destruction of beta cells, these cells 
help in the creation of insulin. Type two is noninsulin-dependent and is caused by aging and 
obesity [12]. Antidiabetic treatments can be seen in vanadium salts and coordination 
compounds. They demonstrated insulin enhancing effects. In 1899, sodium vanadate was given 
to patients of Lyonnet ‘s, and he observed a positive effect on their health. Vanadate was also 
studied in 1977 by Josephson. In his research he saw inhibitory effects towered phosphatases. 
Later research studies involved diabetic rats and showed that sodium orthovanadate with 
drinking water could reverse a majority of diabetic symptoms.  This provoked an increased 
interest in the biological functions of vanadium. First generation vanadium complexes had a bit 
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of a challenge attached with them in that they were needed in high dosages. Further 
generation development of vanadium complexes showed half toxicity as that of the first 
generation complexes, as well as the lower dosage need. There has been much progression in 
the development of treating diabetes with vanadium containing drugs [1,12].  
As stated before, one widely known metallodrug is Cisplatin. While Cisplatin is well-
known and commonly used for anticancer treatment for various cancers; there is a metal that 
has the potential to out shine cisplatin. Finding that particular metal had to be a smart choice. 
One paper takes this challenge head on in looking for that right metal. Looking into other ways 
to attack cancerous cells, other than what has been done before. They looked at metals with 
catalytic potential. Why catalytic drugs? Catalytic drugs were chosen for various purposes. 
These reasons were because catalytic drugs are used in small doses, there is low toxicity levels, 
and there is a well-known potential of cell death from redox reactions. Going down a new path 
to treat cancers, will inevitably help lower the resistance levels that are becoming present 
within cancerous cells, from current treatments. From there it led to the metal compound 
ruthenium and its catalytic potential. Ruthenium has the ability to be a successful catalyst. We 
see this in Ru oxidizing glutathione to its disulfide bond, which eventually leads to cell death 
[1,4,7]. This paper ended up synthesizing several different Ru complexes. The four complexes 
used consisted of either a cyclohexane ring or a furan ring (Figure 2: a- cyclohexane, b- furan). 
Cyclohexane ring and a furan ring were used as substitute ligands because they are used in 
other drug designs. They also have the potential for dissolving in fats, oils, lipids and non-polar 
solvents. Complex 2a-b (figure 2) contains a Schiff base and complex 5a-b (figure 2) contended 
to contain an amine liganded. Both complex 2a-b and 5a-b were the desired product. Past 
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research has shown that shiff base ligands has played a large role in antiproliferative activity. 
Knowing that a shiff base has potential to hinder cell growth, this research was done in hopes 
of seeing if another complex would hinder cell growth. The goal of complex 5a-b was to see if a 
simple change would affect the treatment of cancer cells[4].  
Anticancer Activity and Catalytic Potential of Ruthenium(II)–Arene Complexes with N,O-
Donor Ligands Mohammad Mehdi Haghdoost, Juliette Guard, Golara Golbaghi, and Annie 
Castonguay Inorganic Chemistry 2018 57 (13), 7558-7567 DOI: 10.1021/acs.inorgchem.8b00346 
A variety of tests were performed on the four complexes such as: NMR, high-resolution 
electrospray ionization mass spectrometry (HR-ESI-MS) and elemental analysis, X-ray 
crystallography: on 4a and 5a-b, Hydrolysis, UV−vis. Different spectra were used to help confirm 
     Figure 2: synthesis of  
compounds used 
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the composition of the compounds and allow for a clearer understanding for what they were 
working with.  When the compounds were originally analyzed, after refluxing in ethanol for 5 
hours, by H-NMR it was discovered that their desired products were not present. However, 
unexpected product was produced, complex 4a-b (figure 2). They ended up discovering 
complex 5a-b when the reaction was performed at room temperature, with an excess amount 
of triethylamine. NMR and ESI-MS were also usual for concluding that complex 5a-b were more 
stable then complex 2a-b, this was seen when they were exposed to air for several weeks. Also, 
a hydrolysis was preformed, which concluded that 5 complexes had a hydrolysis rate that was 
10 times slower than 2a-b complexes [4].  
In this research they wanted to look into the complexes ability to hinder cell grow and 
that was done through an MTS assay. Where they tested each complex as well as cis-platin 
against human ovarian cancer cells (A2780), human neuroblastoma (SH-SY5Y), breast 
carcinoma (MCF-7), resistant cis-platin cancerous human breast cell line (T47D), and non-
cancerous breast cells (MCF-12A ) (figure 3). From this test they saw that cis-platin for A2780, 
SH-SY5y, and MCF-7 was the best inhibitor. It wasn’t until they looked at T47D where they saw 
a great resistance to cis-platin and 5a in this case was the best option for the resistant cancer 
cell. Leading to the conclusion that this Ru complex (5a) has a high potential in treating 
someone who is resistant to cis-platin [4]. 
 
Figure 3: Antiproliferative activity 
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Anticancer Activity and Catalytic Potential of Ruthenium(II)–Arene Complexes with 
N,ODonor Ligands Mohammad Mehdi Haghdoost, Juliette Guard, Golara Golbaghi, and Annie 
Castonguay Inorganic Chemistry 2018 57 (13), 7558-7567 DOI: 10.1021/acs.inorgchem.8b00346 
When looking into Ru ability to be an effective catalyst, they looked at NAD+ to its 
reduced form NADH. They wanted to see if Ru could be a catalyst for this well know coenzyme, 
known for critical cellular functions. So, they used Ruthenium as a catalyst and sodium formate 
as the hydrogen donor (figure 4).  
 
 
Anticancer Activity and Catalytic Potential of Ruthenium(II)–Arene Complexes with 
N,O-Donor Ligands Mohammad Mehdi Haghdoost, Juliette Guard, Golara Golbaghi, and Annie 
Castonguay Inorganic Chemistry 2018 57 (13), 7558-7567 DOI: 10.1021/acs.inorgchem.8b00346 
  UV-vis spectra did confirm that 5a was a catalyst for NAD+ to NADH. They also 
obtained turnover frequency (TOF) of the complexes after they were in a water/methanol 
mixture, heated to 60°C. Turnover frequency is the number of moles transformed into the 
desired product/one mole of active site per hour, the larger the TOF, the higher the catalytic 
activity. Showing that 5a did have the higher TOF (figure 5), displaying that more NADH was 
Figure 4: Reduction of NAD+ 
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produced from 5a then the other complexes.  While they did see Ru worked as a catalyst for 
this reduction, however, once this took place the compound could not operate within the cell 
environment. So, what they saw was Ru has a great cytotoxicity and catalytic potential, 
however the two could not work together. Which brought them to the concept of reactive 
oxygen species (ROS) generation. The over production of ROS would produce oxidative stress, 
which eventually leads to cell death[ 4]. 
 
 
Anticancer Activity and Catalytic Potential of Ruthenium(II)–Arene Complexes with 
N,O-Donor Ligands Mohammad Mehdi Haghdoost, Juliette Guard, Golara Golbaghi, and Annie 
Castonguay Inorganic Chemistry 2018 57 (13), 7558-7567 DOI: 10.1021/acs.inorgchem.8b00346 
The main focus was seeing if the Ru complexes, could in fact, produce ROS. Hoping that 
a catalytic drug could select cancerous cells and then generate ROS, leading to cell death within 
Figure 5: TOF values  
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the cancer. There have been clinical trials in the area of ROS generation using two manganese 
porphyrin complexes treating metastatic colorectal cancer. Within this paper’s research they 
used DCFDA (dichlorofluorescin diacetate) and fluorescence radiation for analysis. They test 
each complex against breast cancer cell line, seeing which complex resulted in a greater 
production. From the fluorescence they saw 5a-b complexes had the highest production. 
Complexes 2a-b had little to no production when compared to the control. Cis-platin did exhibit 
generation, however it was lower than 5a-b (figure 6) [4].  
 
 
Anticancer Activity and Catalytic Potential of Ruthenium(II)–Arene Complexes with 
N,O-Donor Ligands Mohammad Mehdi Haghdoost, Juliette Guard, Golara Golbaghi, and Annie 
Castonguay Inorganic Chemistry 2018 57 (13), 7558-7567 DOI: 10.1021/acs.inorgchem.8b00346 
Figure 6: ROS production 
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The overall research was assessing two different structural complexes, consisting of 
either a Schiff base or amine. They wanted to see the effects of a simple change, this change 
was the difference between the Schiff base and amine ligand and whether this change would 
have positive anticancer treatment potentials. This research group did see what they 
potentially wanted to see and that was Ru complexes had promise for antiproliferative activity 
as well as the ability to form ROS from catalyzing a redox reaction. When thinking about future 
research there is a high need for drugs that can reduce the resistance of cells. The problem 
found is that the tolerance for these drugs is growing and metallodrugs could provide an 
answer, as well as help our resistance to these drugs. Metallodrugs hold tremendous potential 
to help mankind overcome drug resistance and to find new cures in medicine. Further research 
into catalytic potential of complex 5a-b, in particular, and their ROS generation could be just 
what is needed in cancer treatments. Metallodrugs have a wide range yet to be explored. The 
simplest modification could end up having the greatest effect [4]. There are disorders and 
disease that could greatly benefit from a deeper understanding of metallodrugs. The hope is 
that people become open to the idea of metallodrugs and try not to only focus on the negative 
connotations. With any drug there is a range of side effects. Whether there is metal present in 
the drug or no metal present they all have their own kind of side effects. Metals can be a risk, 
but there is great potential with metals and drug research. 
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